세계의 치료용 백신 시장(2023-2030년)

Global Therapeutic Vaccines Market - 2023 -2030

US $ 4,350 ￦ 5,990,000

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850 ￦ 6,679,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850 ￦ 10,811,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

개요

치료적 백신 접종은 감염 후 항바이러스 면역을 유도하여 질병의 경과를 바꾸기 위해 시행하는 것입니다. 최종 목적은 숙주의 면역력을 변화시켜 질병을 근절하고 장기적으로 기억하는 것입니다.

나노 생명공학의 급속한 발전은 치료용 암 백신 접종의 발전을 가능하게 했습니다. 치료용 암 백신의 주요 목적은 킬러 T 세포의 활성화를 포함한 세포성 면역 반응을 유도하는 것입니다.

시장 역학: 시장 성장 촉진요인과 시장 성장 억제요인

감염병 증가

감염병 증가는 많은 사람들의 삶에 영향을 미치고 있습니다. 감염병을 예방하기 위해 많은 새로운 치료 백신이 도입되고 있습니다. 치료 백신의 기술 혁신 증가는 시장 성장을 가속할 것으로 예상됩니다.

예를 들어, 미국 질병통제센터(CDC)에 따르면 매년 최대 4억 명이 뎅기열에 감염되는 것으로 추정됩니다. 약 1억 명이 감염되고 4만 명이 중증 뎅기열로 사망합니다.

또한 세계보건기구(WHO) 보고서에 따르면 매년 130만-400만 명의 콜레라 감염자가 발생하며, 세계적으로 21,000-143,000명이 사망하는 것으로 추정하고 있습니다. 콜레라는 심각한 탈수 증상을 동반한 급성 수양성 설사를 유발하는 매우 심각한 질병입니다.

감염병 환자 수가 증가함에 따라 항원에 대한 면역 반응을 일으켜 감염병을 치료하는 치료용 백신에 대한 수요가 증가할 것으로 보입니다.

억제요인

백신 개발에 대한 막대한 자본 지출, 연구개발(R& D) 비용 증가, 복잡한 질병을 대상으로 하는 생물학적 및 기술적 과제, 더 나은 의료 수준과의 경쟁, 안전성과 유효성을 입증하기 위한 대규모 임상시험, 엄격한 규제 등이 예측 기간 동안 시장을 저해하는 요인으로 작용할 것으로 예상됩니다. 시장 성장을 저해할 것으로 예상됩니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter의 Five Forces 분석
• 공급망 분석
• 가격 분석
• 규제 분석
• 러시아·우크라이나 전쟁의 영향 분석
• DMI의 견해

제6장 COVID-19 분석

제7장 유형별

• 항원 백신
• 수지상 세포 백신
• DNA 백신
• 종양 세포 백신

제8장 제품별

• 자가면역질환 백신
• 중독 백신
• 암 백신
• 신경질환 백신
• 감염증 백신
• 기타

제9장 기술별

• 자가 백신
• 동종 백신

제10장 유통 채널별

• 병원 약국
• 소매 약국
• 온라인 약국

제11장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 기타 아시아태평양
• 중동 및 아프리카

제12장 경쟁 구도

• 경쟁 시나리오
• 시장 현황/점유율 분석
• M&A분석

제13장 기업 개요

• Elicio Therapeutics
  • 기업 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 발전
• Argos Therapeutics
• CSL Limited
• Johnson & Johnson
• AstraZeneca Plc
• Merck & Co., Inc.,
• Eli Lilly and Company
• Sanofi
• Dynavax Technologies.
• GSK Pharmaceuticals

제14장 부록

LSH

영문 목차

영문목차

Overview

Therapeutic vaccination is one that is taken after infection to induce antiviral immunity and thereby change the course of the disease. It's ultimate goal is to change host immunity in order to eradicate disease and develop long-term memory.

The rapid advancement of nanobiotechnology has allowed for advancements in therapeutic cancer vaccinations. A therapeutic cancer vaccine's primary purpose is to elicit a cellular immune response, including the activation of killer T cells.

Market Dynamics: Drivers & Restraints

Increase in the prevalence of infectious diseases

The increase in infectious diseases has impacted the lives of a number of people. In order to prevent infections a number of new therapeutic vaccines have been introduced. The increase in innovations of therapeutic vaccines is expected to drive market growth.

For instance, according to the Centers for Disease Control (CDC), it is estimated that each year, up to 400 million people get infected with dengue. Approximately 100 million people get sick from infection, and 40,000 die from severe dengue.

Additionally, according to the report by World Health Organization (WHO), it is stated that researchers have estimated that every year, there are 1.3 to 4.0 million cases of cholera, and 21 000 to 143 000 deaths worldwide due to the infection. Cholera is considered an extremely serious disease that can cause severe acute watery diarrhea with severe dehydration.

The increase in the number of infectious diseases will increase the demand for therapeutic vaccines in order to treat infectious diseases by developing an immune response against the antigens present.

Restraint

Huge capital expenditure on vaccine development, the rising cost of research and development (R&D), biological and technical challenges associated with targeting more complex diseases, competition with better standards of care, the larger scale of clinical studies to prove safety and efficacy, and stringent regulations are the factors the market is expected to get hampered in the forecast period.

Segment Analysis

The global therapeutic vaccines market is segmented based on type, products, technology, distribution channel and region.

Cancer vaccines segment accounted for 38.3% of the market share

The ability to deliver all potential antigens to the immune system is the most essential advantage of cancer vaccines. Cancer vaccines, either allogeneic or autologous, can be created and delivered to patients using irradiation of whole cells or cell lysates.

Cancer vaccines segment has been holding a dominant segment in the therapeutic vaccines market due to the rise in the number of different cancers that can be treated through therapeutic vaccines. It is expected to continue throughout the forecast period. For instance, according to the American Society of Cancer, it is estimated that about 288,930 new cancer cases are to be diagnosed.

Additionally, it is estimated that about 82,290 new bladder cancer cases and 97,610 melanoma cases are to be diagnosed in the year 2023. The availability of tumor cell vaccines is expected to treat cancers. Thus, an increase in the incidence of cancer cases is expected to raise the growth of the segment.

Geographical Analysis

North America is expected to hold a significant position in the global therapeutic vaccines market share

North America is a dominant force in the global therapeutic vaccine market. The rising incidence of chronic infectious diseases, cancer, and Alzheimer's, are the factors that are driving the market growth. It is expected to continue throughout the forecast period.

According to Alzheimer's San Diego Organization, it is estimated that at least one person in America develops Alzheimer's every 67 seconds. It is estimated that nearly 500,000 new cases of Alzheimer's disease will be diagnosed in 2023.

Additionally, according to the American Society of Cancer, it is estimated that about 81,800 new cases of kidney cancer will be diagnosed. Thus, an increase in disease conditions is expected to increase the demand for therapeutic vaccines.

Also, the presence of key manufacturers, increasing investments by pharmaceutical companies for vaccine development in the region, proactive government initiatives, favorable subsidiaries, and a large patient pool are driving the market in North America.

COVID-19 Impact Analysis:

COVID-19 has impacted the growth of the market positively. There is a rise in the demand for therapeutic vaccines during this period. The increase in the cases of COVID-19 has increased the emergency and demand for the production of therapeutic vaccines which have the ability to produce antibodies against the virus.

Competitive Landscape

The leading companies with a significant market share in global therapeutic vaccines include: Elicio Therapeutics, Argos Therapeutics, CSL Limited, Johnson & Johnson, AstraZeneca Plc, Merck & Co., Inc., Eli Lilly and Company, Sanofi, Dynavax Technologies., and GSK Pharmaceuticals among others.

Key Developments

• On January 24, 2023, the Serum Institute of India (SII) launched India's First Indigenously Made Cervical Cancer Vaccine 'CERVAVAC'.
• On May 11, 2023, TechInvention Lifecare India in partnership with Eubiologics Co, South Korea, launched Euvichol-Plus, an oral cholera vaccine in India.

Why Purchase the Report?

• To visualize the global therapeutic vaccines market segmentation based on type, products, technology, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of therapeutic vaccines market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global therapeutic vaccines market report would provide approximately 69 tables, 70 figures, and 183 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Products
• 3.3. Snippet by Technology
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increase in the prevalence of infectious diseases
    • 4.1.1.2.
  • 4.1.2. Restraints
    • 4.1.2.1. High investments in manufacturing
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Antigen Vaccines *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Dendritic Cell Vaccine
• 7.4. DNA Vaccine
• 7.5. Tumor Cell Vaccines

8. By Products

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
  • 8.1.2. Market Attractiveness Index, By Products
• 8.2. Autoimmune Disease Vaccine *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Addiction Vaccine
• 8.4. Cancer Vaccines
• 8.5. Neurological Disease Vaccine
• 8.6. Infectious Disease Vaccine
• 8.7. Others

9. By Technology

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.1.2. Market Attractiveness Index, By Technology
• 9.2. Autologous Vaccines *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Allogeneic Vaccines

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. UK
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Elicio Therapeutics *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Argos Therapeutics
• 13.3. CSL Limited
• 13.4. Johnson & Johnson
• 13.5. AstraZeneca Plc
• 13.6. Merck & Co., Inc.,
• 13.7. Eli Lilly and Company
• 13.8. Sanofi
• 13.9. Dynavax Technologies.
• 13.10. GSK Pharmaceuticals

LIST NOT EXHAUSTIVE.

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us

관련자료